Shares of Clovis Oncology Inc. (NASDAQ:CLVS) shot up 1.4% during mid-day trading on Friday . The company traded as high as $14.19 and last traded at $14.08, with a volume of 256,629 shares changing hands. The stock had previously closed at $13.89.

A number of research firms have recently issued reports on CLVS. Piper Jaffray Cos. began coverage on shares of Clovis Oncology in a report on Monday, April 4th. They issued a “neutral” rating and a $18.00 price objective on the stock. Leerink Swann lifted their price objective on shares of Clovis Oncology from $104.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, March 28th. Vetr downgraded shares of Clovis Oncology from a “buy” rating to a “hold” rating and set a $17.66 price objective on the stock. in a report on Tuesday, June 7th. Credit Suisse Group AG restated a “hold” rating on shares of Clovis Oncology in a report on Wednesday, June 8th. Finally, Mizuho lowered their target price on shares of Clovis Oncology from $21.00 to $15.00 and set a “neutral” rating on the stock in a report on Monday, April 11th. Seven research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $29.25.

The company has a 50-day moving average price of $14.59 and a 200-day moving average price of $17.94. The company’s market capitalization is $552.36 million.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.39) by $0.22. The business’s quarterly revenue was up NaN% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.86) EPS. Equities analysts predict that Clovis Oncology Inc. will post ($8.00) EPS for the current year.

Other institutional investors have recently modified their holdings of the company. California State Teachers Retirement System boosted its position in shares of Clovis Oncology by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 51,609 shares of the biopharmaceutical company’s stock worth $1,806,000 after buying an additional 889 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Clovis Oncology by 6.6% in the fourth quarter. Rhumbline Advisers now owns 30,237 shares of the biopharmaceutical company’s stock worth $1,058,000 after buying an additional 1,880 shares in the last quarter. ProShare Advisors LLC boosted its position in shares of Clovis Oncology by 9.5% in the fourth quarter. ProShare Advisors LLC now owns 36,129 shares of the biopharmaceutical company’s stock worth $1,265,000 after buying an additional 3,125 shares in the last quarter. Finally, Trexquant Investment LP purchased a new position in shares of Clovis Oncology during the fourth quarter worth about $3,170,000.

Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.